We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) and Adolor announced data from Study 014 and provided an update on the clinical development program for alvimopan, also known as Entereg and Entrareg.
ImClone Systems and Bristol-Myers Squibb (BMS) have announced that a Phase III study of Erbitux plus gemcitabine in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.
Wyeth Pharmaceuticals announced that the FDA has extended the review of its new drug application (NDA) for Torisel, an investigational treatment for advanced renal cell carcinoma (RCC).
CytRx has announced positive results of animal stroke studies indicating that its lead drug candidate, arimoclomol, significantly accelerated the recovery of sensory and motor function in an experimental rat model of stroke, even when treatment was withheld for as long as 48 hours after stroke was induced.
Opexa Therapeutics has announced positive top-line data from an open-label, Phase I/II, dose-escalation clinical trial of its investigational T-cell vaccine, Tovaxin, for multiple sclerosis (MS).
Merrimack Pharmaceuticals has initiated a Phase II pilot study to determine the safety and efficacy of its immunomodulator MM-093 in patients suffering from autoimmune uveitis.